Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0PWAOJ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
SGN-CD228A
|
|||||
| Synonyms |
SGN-CD228A
Click to Show/Hide
|
|||||
| Organization |
Seagen (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
HL49
|
Antibody Info | ||||
| Antigen Name |
Melanotransferrin (MELTF)
|
Antigen Info | ||||
| Payload Name |
MMAE
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mal PEG12 based β-glucuronide linker
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Colorectal cancer |
1 Trials
|
||||||||
| Pancreatic cancer |
1 Trials
|
||||||||
| Lung cancer |
1 Trials
|
||||||||
| Pleura mesothelioma |
1 Trials
|
||||||||
| Melanoma |
1 Trials
|
||||||||
| Breast cancer |
1 Trials
|
||||||||
| Unspecific solid tumor |
1 Trials
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Discovered Using Patient-derived Xenograft Model
| Standard Type | Value | Units | Animal Model (No. of PDX) |
|---|---|---|---|
| Tumor Growth Inhibition value (TGI) |
75
|
%
|
NSCLC PDX model
|
| Tumor Growth Inhibition value (TGI) |
100
|
%
|
NSCLC PDX model
|
Discovered Using Cell Line-derived Xenograft Model
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Inclusion: Metastatic/unresectable, relapsed/refractory solid tumors (melanoma, mesothelioma, HER2- breast cancer, NSCLC, CRC, PDAC) with prior therapies per tumor type, measurable disease (RECIST v1.1), ECOG 0-1. Exclusion: Recent malignancies, Grade 2+ neuropathy, retinal disease, prior SGN-CD228A/MMAE exposure.
|
||||
| Administration Dosage |
SGN-CD228A administered into the vein (IV; intravenously)
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04042480 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1 Study of SGN-CD228A in Select Advanced Solid Tumors | ||||
| Primary Endpoint |
The study monitors adverse events (AEs), lab abnormalities, and dose-limiting toxicities (DLTs) over 3.5 years, tracking any untoward medical occurrences in participants administered the investigational drug.
|
||||
| Other Endpoint |
Efficacy endpoints include RECIST v1.1/mRECIST response (for mesothelioma), ORR (CR/PR post-treatment), PFS, OS, and DOR. PK analysis covers Cmax, Tmax, AUC (0-last), and Ctrough for acMMAE, free MMAE, and total antibody, alongside ADA incidence, all assessed over 3.5 years.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT04042480 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 study of SGN-CD228A in select advanced solid tumors. | ||||
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 75% | Positive CD228 expression (CD228+++/++) | ||
| Method Description |
SGN-CD228A was evaluated for antitumor activity in melanoma and NSCLC xenograft and PDX models.SGN-CD228A was administered at a single dose of 3.00 mg/kg.
|
||||
| In Vivo Model | NSCLC PDX model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 100% | Positive CD228 expression (CD228+++/++) | ||
| Method Description |
SGN-CD228A was evaluated for antitumor activity in melanoma and NSCLC xenograft and PDX models.SGN-CD228A was administered at a single dose of 1.00 mg/kg.
|
||||
| In Vivo Model | NSCLC PDX model | ||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 50% | Positive CD228 expression (CD228+++/++) | ||
| Method Description |
SGN-CD228A was evaluated for antitumor activity in melanoma and NSCLC xenograft and PDX models.SGN-CD228A was administered at a single dose of 1.00 mg/kg.
|
||||
| In Vivo Model | Melanoma CDX model | ||||
| In Vitro Model | Cutaneous melanoma | SK-MEL-5 cells | CVCL_0527 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 62.50% | Positive CD228 expression (CD228+++/++) | ||
| Method Description |
SGN-CD228A was evaluated for antitumor activity in melanoma and NSCLC xenograft and PDX models.SGN-CD228A was administered at a single dose of 1.00 mg/kg.
|
||||
| In Vivo Model | Melanoma CDX model | ||||
| In Vitro Model | Cutaneous melanoma | COLO 853 cells | CVCL_2003 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 100% | Positive CD228 expression (CD228+++/++) | ||
| Method Description |
SGN-CD228A was evaluated for antitumor activity in melanoma and NSCLC xenograft and PDX models.SGN-CD228A was administered at a single dose of 1.00 mg/kg.
|
||||
| In Vivo Model | Squamous NSCLC CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | Calu-1 cells | CVCL_0608 | ||
References